Patents Assigned to Immunity Pharma Ltd.
  • PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME
    Publication number: 20240190919
    Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.
    Type: Application
    Filed: February 26, 2024
    Publication date: June 13, 2024
    Applicant: Immunity Pharma Ltd.
    Inventors: Eran OVADIA, Avi BEN-SHIMON
  • Peptide compounds and therapeutic uses of same
    Patent number: 11912790
    Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.
    Type: Grant
    Filed: July 10, 2019
    Date of Patent: February 27, 2024
    Assignee: Immunity Pharma Ltd.
    Inventors: Eran Ovadia, Avi Ben-Shimon
  • PEPTIDE COMPOUNDS AND METHODS OF TREATING DISEASES USING SAME
    Publication number: 20230049549
    Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed. Uses thereof for treating inflammatory or degenerative diseases are also disclosed.
    Type: Application
    Filed: January 14, 2021
    Publication date: February 16, 2023
    Applicant: Immunity Pharma Ltd.
    Inventors: Eran OVADIA, Avi BEN-SHIMON, Ilana COHEN
  • PEPTIDE COMPOUNDS AND THERAPEUTIC USES OF SAME
    Publication number: 20210261615
    Abstract: Isolated peptides capable of reducing the amount of dexamethasone-induced spleen and/or thymus weight loss in a mouse are disclosed as well as uses thereof.
    Type: Application
    Filed: July 10, 2019
    Publication date: August 26, 2021
    Applicant: Immunity Pharma Ltd.
    Inventors: Eran OVADIA, Avi BEN-SHIMON
  • COMPOSITIONS AND METHODS OF USING SAME FOR TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS)
    Publication number: 20210100869
    Abstract: Compositions and methods of using same for treating Amyotrophic Lateral Sclerosis (ALS) are provided. Accordingly there is provided a method of treating ALS in a human subject in need thereof, the method comprising intravenously (IV) administering to the subject 2-5 mg/kg of a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1. Also provided are compositions and unit dosage forms comprising a peptide comprising an amino acid sequence as set forth in SEQ ID NO: 1.
    Type: Application
    Filed: November 26, 2020
    Publication date: April 8, 2021
    Applicant: Immunity Pharma Ltd.
    Inventor: Eran OVADIA